<DOC>
	<DOCNO>NCT01076179</DOCNO>
	<brief_summary>The purpose study investigate tolerability Lopinavir/ritonavir combination new substance .</brief_summary>
	<brief_title>Kaletra Combination With Antiretroviral Agents</brief_title>
	<detailed_description>The Primary Objectives assess tolerability lopinavir/ritonavir standard clinical setting . The Secondary Objectives characterize development viral resistance ass development CD4 T-lymphocyte cell count . All medication prescribe per clinical practice . The Rationale document safety , tolerability clinical outcome therapy regimens include lopinavir/ritonavir new substance , INIs ( integrase inhibitor , CCR5 ( C-C chemokine receptor type 5 ) antagonists new NNRTIs ( non-nucleoside reverse transcriptase inhibitor ) many reason ( intolerability , complex resistant pattern even personal reason ) may result change daily clinical routine lead use newly approve antiretroviral agent combination lopinavir/ritonavir .</detailed_description>
	<mesh_term>Immunologic Deficiency Syndromes</mesh_term>
	<mesh_term>Acquired Immunodeficiency Syndrome</mesh_term>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Lopinavir</mesh_term>
	<mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
	<mesh_term>Anti-Retroviral Agents</mesh_term>
	<mesh_term>Integrase Inhibitors</mesh_term>
	<criteria>Patients ( 18 year old ) Human Immunodeficiency Virus infection , patient therapy lopinavir/ritonavir integrase inhibitor non nucleoside reverse transcriptase inhibitor CCR5 antagonist least 12 week . Hypersensitivity Kaletra ingredient integrase inhibitor non nucleoside reverse transcriptase inhibitor CCR5 antagonist . Severe liver insufficiency . No concommitant astemizole , terfenadine , oral midazolam , triazolam , cisapride , pimozide , amiodarone , ergotamine , dihydroergotamine , ergometrine , methylergometrine , vardenafil St. John 's wort .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>99 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Infection</keyword>
	<keyword>Rilpivirine</keyword>
	<keyword>CCR5 antagonist</keyword>
	<keyword>Etravirine</keyword>
	<keyword>Human Immunodeficiency Virus</keyword>
	<keyword>Maraviroc</keyword>
	<keyword>Safety efficacy</keyword>
	<keyword>Non nucleoside reverse transcriptase inhibitor ( NNRTIs )</keyword>
	<keyword>Integrase inhibitor</keyword>
	<keyword>Raltegravir</keyword>
	<keyword>Kaletra</keyword>
</DOC>